<DOC>
	<DOCNO>NCT02861859</DOCNO>
	<brief_summary>The purpose study evaluate whether add olanzapine 5mg standard antiemetic medication significantly reduce chemotherapy-induced nausea vomit breast cancer patient receive emetogenic chemotherapy regimen anthracycline cyclophosphamide-based chemotherapy platinum-based chemotherapy . To help clinician prescribe antiemetic medication patient-centered , evidence-based cost-effective manner , 've develop world 's first validate risk-stratification tool chemotherapy-induced nausea vomiting ( CINV ) , possible perform trial personalize precision antiemetic therapy breast cancer patient . Despite widespread antiemetic use , chemotherapy-induced nausea vomiting ( CINV ) remain among fear expected side effect chemotherapy breast cancer . Inadequately control CINV significantly reduce patient 's quality life , impair functional activity , lead chemotherapy dose delay reduction , even discontinuation treatment . The merit current antiemetic medication base ability control chemotherapy-induced vomiting , necessarily nausea , nausea major issue breast cancer patient . With olanzapine demonstrate significant promise prevent acute delay nausea , investigator propose evaluate guideline-recommended aprepitant-based triple regimen compare regimen plus olanzapine ( 5 mg ) patient high personal risk CINV . For patient low personal risk CINV investigator also evaluate guideline-recommended double antiemetic regimen compare regimen plus olanzapine ( 5 mg ) .</brief_summary>
	<brief_title>Individualised Versus Standard Care Breast Cancer Patients High-risk Chemotherapy-induced Nausea Vomiting The ILIAD Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Newly diagnose invasive breast cancer ( stage IIII ) schedule receive neo/adjuvant anthracycline/cyclophosphamide platinumbased chemotherapy â‰¥18 year Able provide consent complete studyrelated diary questionnaire . Received previous chemotherapy Symptoms nausea vomit baseline On chronic antiemetic therapy ( e.g . metoclopramide ) ; daily long term oral steroid prior chemotherapy Allergic medical condition make administration olanzapine , aprepitant , 5HT3 antagonist dexamethasone contraindicate Uncontrolled diabetes Known/documented medical/psychiatric illness would interfere patient ' ability complete diary studyrelated questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Breast Carcinoma</keyword>
	<keyword>Breast Tumors</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Antiemetic effect</keyword>
	<keyword>Antiemetic drug</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>